In this review, no evidence of a relationship between SI and GE was identified for different drugs used for the treatment of gastroparesis. This finding questions the use of GE measurement to direct drug development for gastroparesis.
This Special Report discusses the management of OIC in patients with advanced illness, including RELISTOR (methylnaltrexone bromide), a second-line therapeutic option that inhibits opioids from binding to target receptors within the GI tract and does not cross the blood-brain barrier.
Conclusion Dexamethasone is more effective than placebo in improving CRF and quality of life in patients with advanced cancer.
Compared with their peers without PCa, elderly PCa survivors had a two-fold to five-fold greater prevalence of urinary incontinence, which rose with increasing survivorship duration. Observation, surgery, and ADT were each associated with increased urinary bother. These data suggest a substantially greater burden of urinary health problems among elderly PCa survivors than previously recognized.
Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.
Opioids are the most effective and widely studied agents available for palliation of dyspnea in this population, while adjuvant therapies such as oxygen, noninvasive positive pressure ventilation, and fans may also play a role. Other medications (eg, benzodiazepines and low-dose ketamine) may also be useful in select patients. The early involvement of palliative medicine specialists and/or hospice services for dying patients can facilitate optimal symptom management and transitions of care.
Venlafaxine/gabapentin significantly improved hot flashes in cancer patients under hormone manipulation therapies.
Pruritus is a common complaint in systemic sclerosis (SSc) and impairs patients` quality of life. Little is known about the pathogenesis of itch in SSc, but complex and multi-factorial mechanisms of itch are appreciated in many chronic diseases. This review discusses the putative mechanisms of the pathogenesis of itch to better understand the mechanisms that may be relevant to pruritus in SSc. It discusses possible therapeutics in the context of this complex pathogenesis.